BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 27, 2026
Home » Newsletters » BioWorld

BioWorld

March 16, 2026

View Archived Issues
Doctor giving medicine to patient

Pharma USA: R&D not enough – patients need better DTC access

The disjointed health care system that patients face today blocks a significant proportion of them from accessing life-changing, innovative drugs, prompting many in the biopharma industry to explore more direct-to-consumer (DTC) pathways. During Pharma USA, a Reuters Events meeting held in Philadelphia March 16-17, executives from Eli Lilly and Co., Roche Holding AG’s Genentech unit, Amgen Inc. and consulting firm ZS Associates, among others, offered glimpses into a future where R&D is no longer enough. Read More
Tinted Euro symbol

Enodia jumps ahead in Sec61 targeting, adds Kezar’s program

Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers. Read More
Boston Scientific’s Rezūm Water Vapor Therapy

Boston Sci’s Rezūm therapy superior to drugs in treating BPH

Boston Scientific Corp.’s Rezūm Water Vapor Therapy is superior at providing symptom relief for men with benign prostatic hyperplasia (BPH) than combination drug therapy, according to 12-month data from the Vapeur clinical trial. Patients treated with Rezūm, a minimally invasive therapy, also saw a better preservation of their sexual function. Read More
Hand cupping ear to illustration hearing loss

Amplifon acquires GN hearing business for €2.3B

Amplifon SpA signed a definitive agreement with GN Store Nord A/S to acquire its entire hearing business for €2.3 billion (US$2.64 billion) on a cash-free and debt-free basis. The move by Amplifon will see it become a fully vertically integrated global player poised to transform the hearing care industry. Read More
G2gbio-Samsung-Bioepis deal signing

G2Gbio secures license deal, ₩20B investment from Samsung Epis

G2Gbio Inc. secured a ₩20 billion (US$13.35 million) investment from Samsung Epis Holdings Co. Ltd. and a joint research and license agreement for two assets, including a long-acting obesity treatment, with subsidiary Samsung Bioepis Co. Ltd. March 16. Read More
Lee Byoung-chul, CEO, Kanaph

Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio

Multi-modality platform company Kanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale March 16, becoming the first Korean biotech to go public this year. The Seoul-based company’s shares (KOSDAQ:0082N0) climbed to ₩70,000 in intraday trading before closing at ₩50,600 – 153% higher than the offering price. Read More
A simulated cell in the early stages of division.

Digital model simulates the first fully functioning living cell

Entering a cell and watching its entire inner machinery at work, how DNA is copied, how proteins are assembled, or how it splits in two, has been, for decades, an impossible dream. Now, scientists at the University of Illinois have recreated everything that happens inside a cell at molecular scale in an unprecedented computational model. Syn3A is the first 4D digital cell, capable of combining time and space to simultaneously represent all the internal processes that drive the life cycle of a minimal prokaryotic organism. Read More
Dollar symbol with arrow graph

Cytomx soars as early colorectal cancer data beat expectations

Shares of Cytomx Therapeutics Inc. hit a new 52-week high as the company unveiled preliminary data from an ongoing phase I study of varsetatug masetecan (Varseta-M) in late-line metastatic colorectal cancer. 

Read More

ICYMI: Week in review, March 9-13, 2026

A quick look back at top stories. Read More

Biggest gainers and losers for March 9-13, 2026

The top 10 biopharma stock gainers and losers for the week. Read More

Appointments and advancements for March 16, 2026

New hires and promotions in the biopharma and med-tech industries, including: Eclinical, Koru Medical, Ratio. Read More

Financings for March 16, 2026

Biopharma and med-tech companies raising money in public or private financings, including: Cinclus, Equillium, Indivior, Novonesis, Xcath. Read More

In the clinic for March 16, 2026

Clinical updates for biopharma and med tech, including data readouts and publications: Beren, Immutep, Insight Molecular, Sana, Ultragenyx. Read More

Other news to note for March 16, 2026

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AMC Robotics, Aptar, Firefly, Geovax, Hive Digital, Inovio, Insulet, Intuitive Surgical, Koelis, Oncopeptides, Pfizer, Prism, Receptor.AI, Vistagen. Read More

Regulatory actions for March 16, 2026

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aminex, GSK, Mineralys. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 27, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • Chengdu Mfs Pharma synthesizes new compounds for pain

    BioWorld Science
    Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing